91高清自产国产拍,无码免费A级毛片大全,日本 欧美 国产中文字幕,99re热视频这里只有精品视频首页

Inclacumab (anti-CD62p)

功能和特点
  • 规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
  • 反应种属: Cynomolgus,Human,Rat?
  • 亚型: Human IgG4SP
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
Ab175562-100μg (试用装)
申请此免费试用装(?)
作为尊贵的客户,您每年可免费申请三次您选择的不同货号试用装产品,尽享探索与享受!
100μg 期货 Stock Image
Ab175562-1mg
1mg 期货 Stock Image
Ab175562-5mg
5mg 期货 Stock Image
Ab175562-10mg
10mg 期货 Stock Image

基本信息

产品名称 Inclacumab (anti-CD62p)
规格或纯度 Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性 SELP
反应种属 Cynomolgus,Human,Rat?
偶联标记 Unconjugated

产品属性

克隆 Recombinant
Format Whole IgG
亚型 Human IgG4SP
轻链亚型 Kappa
SDS-PAGE 26.8 kDa (Light Chain) & 52.0 kDa (Heavy Chain), under reducing conditions; 178.3 kDa, under non-reducing conditions.
纯化方法 Protein A purified
纯度 >95%
物理外观 Liquid
储存缓冲液 Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂 No
浓度 Lot by Lot
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息 1256258-86-2

关联配体

Ligand ID 12312
名称 inclacumab
别名 RO4905417
类别 Antibody
学名 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
生物活性评价 The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in ).
评价 Inclacumab (formerly RO4905417) is an IgG4κ monoclonal antobody that targets selectin P (CD62; SELP) that was initially designed for potential to promote anti-inflammatory and antithrombotic effects as a mechanism to reduce atherosclerosis. It blocks the interaction between selectin P and its primary ligand, P-selectin glycoprotein ligand-1 (PSGL-1). Inclacumab was later repositioned to reduce vaso-occlusive crises in patients with sickle cell disease.
单字母多肽序列
三字母多肽序列
翻译后修饰
化学修饰
临床描述 This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receive inclacumab or placebo.
This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD). Participants will be randomized to receive either inclacumab or placebo.
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
来源公司 Global Blood Therapeutics
Global Blood Therapeutics
Global Blood Therapeutics

相关文档

质检报告COA

请输入批号:


产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

91高清自产国产拍,无码免费A级毛片大全,日本 欧美 国产中文字幕,99re热视频这里只有精品视频首页

品牌简介

{转码主词}